Table 1.

Inclusion and exclusion criteria.

Inclusion criteria	- Patients diagnosed with CF with clinical signs consistent with CF and sweat chloride >60 mEq/l or two CF-causing mutations identified - An initial or new Pa isolation from sputum cultures during the study period, treated with tobramycin nebulization or tobramycin dry powder (DPI tobramycin)* - Multiple sputum cultures after the end of treatment
Exclusion criteria	- Chronic Pa infection - Patients receiving Pa suppressing therapy - Lung transplantation before Pa isolation - Incomplete exposure and/or outcome data

^*Pa isolation was defined as initial Pa isolation when the patient hadn’t been infected with Pa prior to this Pa isolation. For new Pa isolation, patients had to be free of Pa, defined by the Leeds criteria, whereby all cultures taken in the last 12 months prior to Pa isolation had to be Pa negative.

CF, cystic fibrosis; DPI, dry powder inhalation; Pa, Pseudomonas aeruginosa.